Zetagen Therapeutics Inc.

Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016. Our goal is to help the hundreds of thousands of people diagnosed with metastatic bone cancers and millions of people needing osteologic intervention. This novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in early 2022. In addition to ZetaMet, the Company’s pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet Settable™ and ancillary osteologic treatments including, ZetaFuse, ZetaSet, ZetaDent and ZetaBase.